FDA Approved: DELSTRIGO — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for Delstrigo, a fixed-dose combination HIV-1 therapy (doravirine/lamivudine/tenofovir disoproxil fumarate) by Merck…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• DELSTRIGO (DORAVIRINE, LAMIVUDINE, TENOFOVIR DISOPROXIL FUMARATE)

Snippet

SUPPL AP for DELSTRIGO (DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE)